Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer

By LabMedica International staff writers
Posted on 07 Feb 2025

Cancer biomarkers are valuable tools for early diagnosis as their concentration in body fluids, such as serum, can be measured to detect the disease at an earlier stage. More...

Additionally, serum levels of these biomarkers can change as cancer treatment progresses, allowing for monitoring that helps adjust treatment doses and assess its effectiveness, thus enabling precision medicine that can improve patient outcomes. However, the detection and quantification of cancer biomarkers are typically expensive, time-consuming, and require highly trained personnel, limiting these processes to specialized laboratory settings. In contrast, point-of-care testing (POCT) is recognized for its ability to speed up diagnosis, optimize patient care, and reduce healthcare costs. Biosensors, which are low-cost, non-invasive (or minimally invasive) devices, are ideal for POCT, offering a way to measure biomarkers' concentrations and enabling early cancer detection and therapy monitoring.

Researchers from Cranfield University (Cranfield, UK) have developed a new, low-cost, and fast-response sensor to detect lung cancer biomarkers, paving the way for screening tools that could detect the disease even before symptoms appear. Similar to the design of glucose monitoring devices, the sensor provides results from a blood sample in just 40 minutes. This innovative technology, featured in the journal Biosensors, has the potential to assist clinicians in identifying patients at higher risk for lung cancer and in tailoring treatments for those already diagnosed, thus facilitating a ‘precision medicine’ approach. Over the course of a three-year research project, the team created the sensors to screen for two key lung cancer biomarkers in a blood sample and successfully demonstrated the concept in a laboratory setting.

Their study focused on developing highly sensitive sensors for two primary lung cancer biomarkers: neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA). The sensors were tested with both buffer and human samples and achieved clinically relevant detection limits for both biomarkers. The findings suggest that this technology holds considerable promise as a valuable tool for the early and accurate detection of lung cancer. The rapid and straightforward test enables clinical staff to identify individuals at higher risk of lung cancer and refer them for further diagnostic testing. This proactive strategy supports early detection, which can lead to improved outcomes. Furthermore, the test can be utilized during treatment to monitor how chemotherapy or other therapies are impacting the cancer.

“At the moment lung cancer screening tests can be expensive and take a long time,” said Dr. Iva Chianella, Senior Lecturer in Bio-sensors and Functional Polymers. “Although it’s early stages, the sensor we have developed holds great promise of early detection, which can lead to prompt treatments with higher patients’ survival rates.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.